Background: To compare the effects of baked flaxseed versus those who received a placebo on constipation symptom scores, weight, glycemic and lipid control in constipated patients with type 2 diabetes (T2D).
Methods: In a single-blinded, randomized controlled trial, 53 constipated patients with T2D with body mass index (BMI) 20.5-48.9 kg/m received either 10 g of flaxseed pre-mixed in cookies twice per day or placebo cookies for 12 weeks. The constipation symptom scores, BMI, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), and lipid profile were determined at the beginning and end of 4, 8, and 12-week period. Constipation was evaluated with a stool diary (ROME III).
Results: After the 12-week intervention, constipation symptom scores (2.46), weight (- 3.8 kg), BMI (- 1.5 kg/m), FPG (- 26.7 mg/dl), cholesterol (- 37.3 mg/dl), triglycerides (- 10.4 mg/dl), LDLC (- 21.0 mg/dl), HDLC (4.7 mg/dl), cholesterol/ HDLC ratio (- 1.4 mg/dl) significantly decreased from baseline in the flaxseed group (all -values < 0.05). The differences of absolute change of constipation symptom scores (2.46 vs. 0.41), weight (- 3.8 vs. 0.0 kg), BMI (- 1.5 vs.-0.1 kg/m), FPG (- 26.7 vs.-1.9 mg/dl), >HbA1c (- 0.8 vs. 1.0%), cholesterol (- 37.3 vs. -10.4 mg/dl), LDLC (- 21.0 vs. -4.3 mg/dl), and HDLC (4.7 vs. -4.4 mg/dl) between the flaxseed and placebo groups were statistically significant (all -values < 0.05). The compliance was good and no adverse effects were observed.
Conclusion: In constipated patients with T2D, flaxseed cookies used as a snack may be a useful tool for decreasing constipation symptoms, weight, glycemic and lipid levels.
Trial Registration: irct.ir: IRCT20110416006202N2.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944250 | PMC |
http://dx.doi.org/10.1186/s12986-018-0273-z | DOI Listing |
Dig Dis Sci
January 2025
Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.
Background: Chronic constipation, diarrhea, and fecal incontinence (FI) are prevalent with significant impact on quality of life and healthcare utilization. Thyroid dysfunction was recognized as a potential contributor to bowel disturbances in selected populations, but the strength/consistency of this association remain unclear.
Aims: To investigate the relationship between thyroid function and bowel health measures (constipation, diarrhea, and FI) in a nationally representative sample of the U.
Eur Spine J
January 2025
Department of Neurosurgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Background: Giant sacral and presacral schwannomas are very rare conditions and their prevalence is estimated to account for only 0.3 to 3.3% of overall schwannomas.
View Article and Find Full Text PDFSci Rep
January 2025
Faculty of Medicine, Department of Gastroenterology, Giresun University, Giresun, Turkey.
The primary objective of this study was to evaluate the clinical, laboratory, and histological characteristics of solitary rectal ulcer syndrome (SRUS) and assess the outcomes associated with various management strategies. This retrospective observational study was conducted at Giresun Education and Research Hospital. This study included patients diagnosed with SRUS between January 2020 and January 2024.
View Article and Find Full Text PDFAm J Transl Res
December 2024
Anorectal Department, Suining Central Hospital Suining 629000, Sichuan, China.
Objectives: This study focuses on analyzing the efficacy of lactulose oral solution combined with Macrogol 4000 Powder in the treatment of functional constipation (FC).
Methods: A total of 125 FC patients were selected, with 60 cases in a control group, who were treated with lactulose oral solution alone, and 65 cases in a research group, who were treated with lactulose oral solution combined with Macrogol 4000 Powder. The two groups were analyzed and compared in terms of efficacy, symptom recovery, Bristol Stool Form Scale (BSFS) and Wexner Constipation Scale (WCS) scores, adverse effects, serum indices, and Patient Assessment of Constipation Quality of Life (PAC-QOL).
JGH Open
January 2025
Department of Nursing Hamad Medical Corporation Doha Qatar.
Background And Aim: Lubiprostone increases chloride and water secretion in the intestines, and several studies have demonstrated the efficacy of lubiprostone in treating functional constipation. Several new clinical trials have emerged since the previous meta-analysis conducted in 2020. We conducted this updated meta-analysis to assess clinical efficacy of lubiprostone in these patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!